Measuring the individual quality of life of patients with prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 11, Issue 4, 2008, Pages 390-396

  Stone, P C ^a   Murphy, R F ^b   Matar, H E ^a   Almerie, M Q ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b St Joseph's Hospice   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; FAMILY LIFE; FUNCTIONAL ASSESSMENT CANCER THERAPY PROSTATE QUESTIONNAIRE; HEALTH; HUMAN; LEISURE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROPSYCHOLOGICAL TEST; PATIENT MOBILITY; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; SCHEDULE FOR THE EVALUATION OF THE INDIVIDUAL QUALITY OF LIFE DIRET WEIGHING; SEMI STRUCTURED INTERVIEW; SEXUALITY;

HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 56249133827     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2008.16     Document Type: Article

References (21)

1. Fallowfield L. Quality of life: A new perspective for cancer patients. Nat Rev 2002; 2: 873-879.
2. Dijkers M. Individualization in quality of life measurement: Instruments and approaches. Arch Phys Med Rehabil 2003; 84: S3-S14.
3. Hays RD. Generic versus disease-targeted instruments.In: Fayers P, Hays R (eds). Assessing Quality of Life in Clinical Trials,2nd edn. OUP: Oxford, 2005; pp 3-8.
4. Cella D, Tulsky D, Gray G, Sarafian B, Linn E, Bonomi A et al. The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 1993; 11: 570-579.
5. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy - prostate instrument. Urology 1997; 50: 920-928.
6. O'Boyle CA, McGee H, Hickey A, O'Malley K, Joyce CR. Individual quality of life in patients undergoing hip replacement. Lancet 1992; 339: 1088-1091.
7. O'Boyle CA, Hofer S, Ring L. Individualised quality of life.In: Fayers P, Hays R (eds). Assessing Quality of Life in Clinical Trials, 2nd edn. OUP: Oxford, 2005; pp 225-242.
8. Waldron D, O'Boyle CA, Kearney M, Moriarty M, Carney D. Quality-of-life measurement in advanced cancer: Assessing the individual. J Clin Oncol 1999; 17: 3603-3611.
9. Willener R, Hantikainen V. Individual quality of life following radical prostatectomy in men with prostate cancer. Urol Nurs 2005; 25 88-90.
10. Broadhead JK, Robinson JW, Atkinson MJ. A new quality-of-life measure for oncology: The SEIQoL. J Psychosoc Oncol 1998; 16: 21-35. (20 ref).
11. Hickey AM, Bury G, O'Boyle CA, Bradley F, O'Kelly FD, Shannon W. A new short form individual quality of life measure (SEIQoL-DW): Application in a cohort of individuals with HIV/AIDS. (see comments). BMJ 1996; 313: 29-33.
12. Browne JP, O'Boyle CA, McGee HM, McDonald NJ, Joyce CR. Development of a direct weighting procedure for quality of life domains. Qual Life Res 1997; 6: 301-309.
13. Waldron D, O'Boyle CA, Kearney M, Moriarty M, Carney D. Quality of life measurement in advanced cancer: Assessing the individual. J Clin Oncol 1999; 17: 3603-3611.
14. Sprangers MAG. Response-shift bias: A challenge to the assessment of patients' quality of life in cancer clinical trials. Cancer Treat Rev 1996; 22: 55-62.
15. Esper P, Pienta KJ. Development of a new instrument for measuring quality of life in patients undergoing therapy for prostate cancer (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 1995; 36.
16. Lee WR, Hall MC, McQuellon RP, Case LD, McCullough DL. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2001; 51: 614-623.
17. Feigenberg SJ, Lee WR, Desilvio ML, Winter K, Pisansky TM, Bruner DW et al. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys 2005; 62: 956-964.
18. Robinson JW, Saliken JC, Donnelly BJ, Barnes P, Guyn L. Quality-of-life outcomes for men treated with cryosurgery for localized prostate carcinoma. Cancer 1999; 86: 1793-1801.
19. Robinson JW, Donnelly BJ, Saliken JC, Weber BA, Ernst S, Rewcastle JC. Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. Urology 2002; 60 (2 Suppl 1): 12-18.
20. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (see comment). N Engl J Med 2004; 351 1502-1512.
21. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005; 23: 455-460.